MX369656B - Insulina de accion prolongada y uso de la misma. - Google Patents
Insulina de accion prolongada y uso de la misma.Info
- Publication number
- MX369656B MX369656B MX2016009434A MX2016009434A MX369656B MX 369656 B MX369656 B MX 369656B MX 2016009434 A MX2016009434 A MX 2016009434A MX 2016009434 A MX2016009434 A MX 2016009434A MX 369656 B MX369656 B MX 369656B
- Authority
- MX
- Mexico
- Prior art keywords
- long
- insulin
- acting insulin
- acting
- blood
- Prior art date
Links
- 102000016261 Long-Acting Insulin Human genes 0.000 title abstract 3
- 108010092217 Long-Acting Insulin Proteins 0.000 title abstract 3
- 229940100066 Long-acting insulin Drugs 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 3
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000003746 Insulin Receptor Human genes 0.000 abstract 1
- 108010001127 Insulin Receptor Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un análogo de insulina que presenta una afinidad reducida de la unión al receptor de insulina con el propósito de aumentar la vida media en sangre de la insulina, y a una insulina de acción prolongada, a un conjugado, y a un método de preparación de una insulina de acción prolongada que la utilice.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140006938 | 2014-01-20 | ||
| PCT/KR2015/000576 WO2015108398A1 (ko) | 2014-01-20 | 2015-01-20 | 지속형 인슐린 및 그 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009434A MX2016009434A (es) | 2017-01-18 |
| MX369656B true MX369656B (es) | 2019-11-15 |
Family
ID=53543214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009434A MX369656B (es) | 2014-01-20 | 2015-01-20 | Insulina de accion prolongada y uso de la misma. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10253082B2 (es) |
| EP (1) | EP3098235A4 (es) |
| JP (1) | JP2017505141A (es) |
| KR (1) | KR102406654B1 (es) |
| CN (2) | CN105916877A (es) |
| AU (1) | AU2015206890B2 (es) |
| BR (1) | BR112016016578A2 (es) |
| CA (1) | CA2937168A1 (es) |
| CL (1) | CL2016001844A1 (es) |
| CR (1) | CR20160376A (es) |
| DO (1) | DOP2016000176A (es) |
| EA (1) | EA201691374A1 (es) |
| EC (1) | ECSP16068524A (es) |
| IL (1) | IL246782B (es) |
| MA (3) | MA43289B1 (es) |
| MX (1) | MX369656B (es) |
| MY (1) | MY186251A (es) |
| PE (1) | PE20161153A1 (es) |
| PH (1) | PH12016501414B1 (es) |
| SG (1) | SG11201605680PA (es) |
| WO (1) | WO2015108398A1 (es) |
| ZA (1) | ZA201605626B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101922317B1 (ko) | 2014-01-20 | 2018-11-26 | 클리브 바이오사이언스 인코포레이티드 (클리브) | p97 복합체의 저해제로서 융합된 피리미딘 |
| SG10201809457YA (en) | 2014-11-21 | 2018-11-29 | Merck Sharp & Dohme | Insulin receptor partial agonists |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| KR20170036643A (ko) * | 2015-09-24 | 2017-04-03 | 한미약품 주식회사 | 인슐린의 제조 방법 |
| KR102698929B1 (ko) * | 2016-09-23 | 2024-08-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
| EP3578204A4 (en) * | 2017-02-03 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | BIOACTIVE SUBSTANCE CONJUGATE WITH ENHANCED DURABILITY AND ITS USE |
| MX2019011297A (es) * | 2017-03-23 | 2019-11-12 | Hanmi Pharm Ind Co Ltd | Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo. |
| WO2019066603A1 (ko) * | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| KR102646845B1 (ko) | 2018-08-08 | 2024-03-14 | 주식회사 대웅제약 | 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법 |
| CA3122636A1 (en) | 2018-12-11 | 2020-06-18 | Sanofi | Insulin analogs having reduced insulin receptor binding affinity |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| EP4130027A4 (en) | 2020-03-31 | 2024-08-14 | Hanmi Pharm. Co., Ltd. | NEW IMMUNOACTIVE INTERLEUKIN-2 ANALOGUE |
| CN115894720B (zh) * | 2023-01-16 | 2024-07-09 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| US5422339A (en) * | 1991-03-19 | 1995-06-06 | Joslin Diabetes Center, Inc. | Peptides having insulin autoantibody but not insulin receptor binding capacity |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2234560T3 (es) | 1999-01-06 | 2005-07-01 | Genentech, Inc. | Variante mutante del factor de crecimiento de tipo insulina (igf-i). |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| BRPI0409600A (pt) | 2003-04-29 | 2006-04-18 | Lilly Co Eli | análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina |
| PL1648933T3 (pl) | 2003-07-25 | 2010-01-29 | Conjuchem Biotechnologies Inc | Długo działające pochodne insuliny i związane z tym sposoby |
| ES2438098T3 (es) | 2003-11-13 | 2014-01-15 | Hanmi Science Co., Ltd. | Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo |
| CN102660614A (zh) * | 2005-08-16 | 2012-09-12 | 诺沃-诺迪斯克有限公司 | 制备成熟胰岛素多肽的方法 |
| ES2542146T3 (es) * | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | Insulinas extendidas PEGiladas. |
| WO2008049711A1 (en) * | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| US7790677B2 (en) | 2006-12-13 | 2010-09-07 | Elona Biotechnologies | Insulin production methods and pro-insulin constructs |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| EP2017288A1 (en) | 2007-07-16 | 2009-01-21 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
| EP2170945A1 (en) * | 2007-07-16 | 2010-04-07 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
| WO2009022013A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| ES2612736T3 (es) | 2007-11-16 | 2017-05-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| DE102008025008A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| CN101970476B (zh) | 2008-01-09 | 2014-08-27 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的胰岛素衍生物 |
| KR20100111682A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
| ES2618073T3 (es) * | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| MX2010009850A (es) * | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| HUE048608T2 (hu) | 2008-10-17 | 2020-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
| EP2376521B1 (en) | 2008-12-19 | 2016-04-13 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
| KR20110137819A (ko) | 2009-03-27 | 2011-12-23 | 글락소 그룹 리미티드 | 약물 융합체 및 컨쥬게이트 |
| US20120184488A1 (en) * | 2009-09-01 | 2012-07-19 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
| KR101058209B1 (ko) | 2009-12-30 | 2011-08-22 | 전자부품연구원 | Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법 |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| KR101330868B1 (ko) * | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
| KR101324828B1 (ko) | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
| US8940860B2 (en) * | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CA2806399A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| SG192038A1 (en) | 2011-01-20 | 2013-08-30 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| CN103635602B (zh) | 2011-03-02 | 2016-08-31 | 欧瑞康表面解决方案股份公司，普费菲孔 | 用于在润滑条件下通过摩擦应用改进磨损和摩擦性能的用含金属碳层涂布的滑动组件 |
| CN102675452B (zh) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
| EP2705325B1 (en) | 2011-05-03 | 2015-04-08 | Teijin Aramid B.V. | Antiballistic panel |
| EA201391764A1 (ru) | 2011-06-02 | 2014-07-30 | Пролор Байотек Инк. | Агонисты рецептора glp-1/глюкагона длительного действия |
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| SG10201604564XA (en) | 2011-06-10 | 2016-07-28 | Hanmi Science Co Ltd | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
| HRP20190265T1 (hr) | 2011-06-17 | 2019-04-05 | Hanmi Science Co., Ltd. | Konjugat koji sadrži oksintomodulin i fragment imunoglobulina i njegova uporaba |
| US9165768B2 (en) | 2011-12-16 | 2015-10-20 | Lg Innotek Co., Ltd. | Method for deposition of silicon carbide and silicon carbide epitaxial wafer |
| US20150299286A1 (en) | 2012-01-20 | 2015-10-22 | Case Western Reserve University | Glutamic acid-stabilized insulin analogues |
| KR101665009B1 (ko) | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
| AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| TWI816739B (zh) | 2012-11-06 | 2023-10-01 | 南韓商韓美藥品股份有限公司 | 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑 |
| CA2901873C (en) | 2013-02-26 | 2022-05-03 | Hanmi Pharm. Co., Ltd. | Novel insulin analog and use thereof |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| KR101676542B1 (ko) | 2014-12-30 | 2016-11-16 | 건국대학교 산학협력단 | 프로인슐린의 면역학적 용도 |
-
2015
- 2015-01-20 CN CN201580004573.4A patent/CN105916877A/zh active Pending
- 2015-01-20 CR CR20160376A patent/CR20160376A/es unknown
- 2015-01-20 PE PE2016001252A patent/PE20161153A1/es unknown
- 2015-01-20 MA MA43289A patent/MA43289B1/fr unknown
- 2015-01-20 EP EP15737856.3A patent/EP3098235A4/en not_active Withdrawn
- 2015-01-20 EA EA201691374A patent/EA201691374A1/ru unknown
- 2015-01-20 AU AU2015206890A patent/AU2015206890B2/en not_active Ceased
- 2015-01-20 BR BR112016016578A patent/BR112016016578A2/pt not_active Application Discontinuation
- 2015-01-20 CN CN202311024383.1A patent/CN116987172A/zh active Pending
- 2015-01-20 JP JP2016564933A patent/JP2017505141A/ja active Pending
- 2015-01-20 MA MA39301A patent/MA39301A1/fr unknown
- 2015-01-20 MX MX2016009434A patent/MX369656B/es active IP Right Grant
- 2015-01-20 CA CA2937168A patent/CA2937168A1/en not_active Abandoned
- 2015-01-20 MA MA46146A patent/MA46146A1/fr unknown
- 2015-01-20 WO PCT/KR2015/000576 patent/WO2015108398A1/ko not_active Ceased
- 2015-01-20 US US15/113,027 patent/US10253082B2/en active Active
- 2015-01-20 SG SG11201605680PA patent/SG11201605680PA/en unknown
- 2015-01-20 MY MYPI2016702501A patent/MY186251A/en unknown
- 2015-01-20 KR KR1020150009433A patent/KR102406654B1/ko active Active
-
2016
- 2016-07-14 DO DO2016000176A patent/DOP2016000176A/es unknown
- 2016-07-14 IL IL246782A patent/IL246782B/en not_active IP Right Cessation
- 2016-07-18 PH PH12016501414A patent/PH12016501414B1/en unknown
- 2016-07-20 CL CL2016001844A patent/CL2016001844A1/es unknown
- 2016-08-15 ZA ZA2016/05626A patent/ZA201605626B/en unknown
- 2016-08-19 EC ECIEPI201668524A patent/ECSP16068524A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL246782A0 (en) | 2016-08-31 |
| KR20150087130A (ko) | 2015-07-29 |
| JP2017505141A (ja) | 2017-02-16 |
| PH12016501414A1 (en) | 2016-09-14 |
| ECSP16068524A (es) | 2018-11-30 |
| EP3098235A4 (en) | 2017-10-18 |
| CL2016001844A1 (es) | 2017-01-06 |
| CA2937168A1 (en) | 2015-07-23 |
| MA46146A1 (fr) | 2020-12-31 |
| AU2015206890B2 (en) | 2019-05-23 |
| MX2016009434A (es) | 2017-01-18 |
| MY186251A (en) | 2021-06-30 |
| US20170101455A1 (en) | 2017-04-13 |
| WO2015108398A1 (ko) | 2015-07-23 |
| EA201691374A1 (ru) | 2016-12-30 |
| MA43289B1 (fr) | 2019-12-31 |
| BR112016016578A2 (pt) | 2017-10-03 |
| EP3098235A1 (en) | 2016-11-30 |
| KR102406654B1 (ko) | 2022-06-10 |
| CN105916877A (zh) | 2016-08-31 |
| AU2015206890A1 (en) | 2016-08-04 |
| CR20160376A (es) | 2016-10-07 |
| PE20161153A1 (es) | 2016-10-27 |
| DOP2016000176A (es) | 2017-02-15 |
| MA39301A1 (fr) | 2018-01-31 |
| IL246782B (en) | 2020-01-30 |
| CN116987172A (zh) | 2023-11-03 |
| ZA201605626B (en) | 2017-11-29 |
| US10253082B2 (en) | 2019-04-09 |
| PH12016501414B1 (en) | 2020-10-30 |
| SG11201605680PA (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501414A1 (en) | Long-acting insulin and use thereof | |
| SA518400491B1 (ar) | نظير إنسولين جديد واستخدامه | |
| EP3141276A4 (en) | Safety insulin pen needle | |
| IL246661B (en) | Human antibodies to pd–l1 | |
| SG10201809427SA (en) | Insulin receptor partial agonists | |
| IL247740A0 (en) | Antibodies that bind to cd3 epsilon from human and cynomolgus | |
| GB201414499D0 (en) | Method and system for delivering funding options to a user | |
| MA40386A (fr) | Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci | |
| MX2016009858A (es) | Fusiones anti proteína convertasa subtilisina/kexina tipo 9 (anti-pcsk9)n péptido 1 similar a glucagón (glp-1) y métodos de uso. | |
| EP3171888A4 (en) | Chromatography process for purification of inlsulin and insulin analogs | |
| MX2015003034A (es) | Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso. | |
| EP3231432A4 (en) | Agent for hypodermic injections and production method for syringes containing agent for hypodermic injections | |
| NZ719745A (en) | Soluble fc gamma receptor for treatment of autoimmune bullous diseases | |
| PL3191106T3 (pl) | Kompozycja zawierająca mikroalgę wzbogaconą w krzem do stosowania terapeutycznego | |
| AU2014900562A0 (en) | A system and a method for facilitating the administering of a healthcare program to a patient | |
| PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
| IN2014MU01191A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |